Clinical Trial Update: A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta [Phase 4]

View source ↗

Summary

Phase 4 study evaluating glycosphingolipid clearance in Fabry disease patients who switch from agalsidase alfa to agalsidase beta.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• agalsidase alfa (agalsidase alfa)
• agalsidase beta (agalsidase beta)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Fabry Disease | Phase 4 | Status: COMPLETED | Results posted: 2014-07-10